p63 antibody | knockout validation | Santa Cruz 4A4
DOI
//dx.doi.org/10.13070/ko.en.6.1824
Date
2016-11-19

This is a knockout-validated antibody summary, based on the publication "IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG2a

Company: Santa Cruz

Antibody: p63

Catalog number: 4A4

Summary: Mouse monoclonal IgG2a recommended for detection of p63 isoforms of mouse, rat and

human origin by western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, flow cytometry and ELISA.

Validation Method

Western blot

Sample

Western blot analysis in ΔNp63fl/fl;p53−/− MEFs before (ΔNp63fl/fl;p53−/−) and after (ΔNp63Δ/Δ;p53−/−) Ad-cre administration .

Primary incubation

1:500 dilution.

Secondary incubation

Horseradish peroxidase-conjugated antibodies at 1:5,000 dilution (Jackson Lab).

Detection

Using the ECL Plus Kit (Amersham) following the manufacturer’s protocol and x-ray autoradiography.

Figure

Please see Extended Data Figure 5a in the article [1].

Notes

The product is no longer available at SCBT. 

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Venkatanarayan A, Raulji P, Norton W, Chakravarti D, Coarfa C, Su X, et al. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature. 2015;517:626-30 pubmed publisher